Concomitantly, high DNAJC15 expression levels have been associated with increased responsiveness to paclitaxel, topotecan and cisplatin (CDDP) in ovarian cancer (OC) [5,12,18]. Here, DNAJC15 is linked to ovarian carcinoma.